 |
|||||||||||||
|
| All | Since 2019 | |
| Citation | 5450 | 3969 |
| h-index | 23 | 20 |
| i10-index | 134 | 84 |
Search
News & Updation
A REVIEW ON: MONOCLONAL ANTIBODIESMadhuri D. Ghadage*, Mrs. A.P. Bedse
Dept of Pharmaceutics, SMBT College of Pharmacy, Nandi Hills, Dhamangaon, Tal-Igatpuri Dist-Nashik (M.S.) India.
ABSTRACT More than 20 monoclonal antibodies have been approved by the US Food and Drug Administration. Kolher and Milstein have first developed the hybridoma technology for monoclonal antibody production. This hybridoma technology has been further improved with chimeric and humanized monoclonal antibody. Further recombinant DNA technology has overcome most of the disadvantages of hybridoma technology and human monoclonal antibody. Monoclonal antibodies are attractive therapeutic drug candidate for disease targeting as Monoclonal antibodies have been valuable tool as diagnostic reagent in clinical diagnosis. Monoclonal antibodies are used in diagnosis of hepatitis, AIDs and treatment of infections and cancers. Monoclonal antibody drugs show desirable characteristics including solubility, stability, long persistence in the body, high selectivity, specificity and low risk for bioconversion to toxic metabolites. The aim of present article is to review the advances in development of monoclonal antibody production technologies, use of monoclonal antibodies as research, diagnostic reagents and quality control of monoclonal antibodies. Keywords: Monoclonal antibody, hybridoma, ELISA, Radioimmunotherapy. [Download Article] [Download Certifiate] |
